Medical Treatment of Parkinson Disease

Neurologic Clinics

Volumn 27, Issue 3, 2009, Pages 605-631

  Stacy, Mark ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dyskinesia; Hallucination; Post synaptic; Pre synaptic; Punding; REM behavior disorder

Indexed keywords

AMANTADINE; APOMORPHINE; ARIPIPRAZOLE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LISURIDE; MEMANTINE; MONOAMINE OXIDASE B INHIBITOR; OLANZAPINE; PERGOLIDE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RASAGILINE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; TOCOPHEROL; TOLCAPONE; UNINDEXED DRUG;

ADJUVANT THERAPY; AGRANULOCYTOSIS; ALZHEIMER DISEASE; ANOREXIA; AREA UNDER THE CURVE; AUTONOMIC DYSFUNCTION; BALANCE IMPAIRMENT; BRADYKINESIA; BRAIN DEPTH STIMULATION; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMPULSION; CONFUSION; CONTINUOUS INFUSION; DEMENTIA; DIARRHEA; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG COMPETITION; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSPEPSIA; EOSINOPHILIA; ERYTHROMELALGIA; EXTRAPYRAMIDAL SYNDROME; FIRST PASS EFFECT; FOOD; FOOD DRUG INTERACTION; HALLUCINATION; HEART ARRHYTHMIA; HUMAN; HYPERSEXUALITY; HYPERTENSIVE CRISIS; INFECTION; INJECTION SITE NODULE; LEG EDEMA; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; MUSCLE HYPERTONIA; MUSCLE RIGIDITY; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL GAMBLING; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SENSORY DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREMOR; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE; VASOCONSTRICTION; VOMITING; WEIGHT REDUCTION; YAWNING;

AMANTADINE; ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; COGNITION DISORDERS; CORPUS STRIATUM; DIGESTIVE SYSTEM PROCESSES; DOPAMINE AGONISTS; ENZYME INHIBITORS; HUMANS; HYPOTENSION, ORTHOSTATIC; LEVODOPA; MENTAL DISORDERS; MONOAMINE OXIDASE INHIBITORS; MOTOR ACTIVITY; MOVEMENT DISORDERS; NEURONS; PARKINSON DISEASE; SLEEP DISORDERS; SUBSTANTIA NIGRA;

EID: 67449095164     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2009.04.009     Document Type: Review

References (172)

1. Samii A., Nutt J.G., and Ransom B.R. Parkinson's disease. Lancet 363 9423 (2004) 1783-1793
2. Hampton T. Parkinson disease registry launched. JAMA 293 2 (2005) 149
3. Weintraub D., Comella C.L., and Horn S. Parkinson's disease - part 1: pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care 14 2 Suppl (2008) S40-S48
4. Jankovic J. Pathophysiology and assessment of parkinsonian symptoms and signs. In: Pahwa R., Lyons K.E., and Koller W.C. (Eds). Handbook of Parkinson's Disease. 4th edition (2007), Taylor & Francis Group LLC, New York 49-76
5. Chaudhuri K.R., Healy D.G., Shapira A.H., and National Institute for Clinical Excellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5 (2006) 235-245
6. Olanow C.W., Agid Y., Mizuno Y., et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19 9 (2004) 997-1005
7. Dewey Jr. R.B. Management of motor complications in Parkinson's disease. Neurology 62 Suppl 4 (2004) S3-S7
8. Jankovic J. Levodopa strengths and weaknesses. Neurology 58 Suppl 1 (2002) S19-S32
9. Jankovic J. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord 20 Suppl 11 (2005) S11-S16
10. Marjama-Lyons J.M., and Koller W.C. Parkinson's disease. Update in diagnosis and symptom management. Geriatrics 56 8 (2001) 24-30 33
11. Obeso J.A., Grandas F., Vaamonde J., et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 39 Suppl 2 (1989) 11-19
12. Marras C., and Lang A. Changing concepts in Parkinson disease: moving beyond the decade of the brain. Neurology 70 (2008) 1996-2003
13. Waters C.H., Sethi K.D., Hauser R.A., et al., The Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord 19 4 (2004) 426-432
14. Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet 33 2 (1997) 91-102
15. Mercuri N.B., Scarponi M., Bonci A., et al. Monoamine oxidase inhibition causes a long-term prolongation of the dopamine-induced responses in rat midbrain dopaminergic cells. J Neurosci 17 7 (1997) 2267-2272
16. Demarcaida J.A., Schwid S.R., White W.B., et al. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 21 10 (2006) 1716-1721
17. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59 12 (2002) 1937-1943
18. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62 2 (2005) 241-248
19. Olanow C.W., Hauser R.A., Jankovic J., et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 23 15 (2008) 2194-2201
20. Rascol O., Brooks D.J., Melamed E., et al., for the LARGO Study Group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365 9463 (2005) 947-954
21. Clarke C.E. Rasagiline for motor complications in Parkinson's disease. Lancet 365 9463 (2005) 914-916
22. Azilect [package insert] (2006), Teva Pharmaceutical Industries Ltd, Kfar Saba, Israel
23. Shin H.-S. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 25 6 (1997) 657-662
24. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 3 (1993) 176-183
25. Shoulson I., Oakes D., Fahn S., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of Parkinsonism trial. Ann Neurol 51 5 (2002) 604-612
26. Cedarbaum J.M., Toy L.H., and Green-Parsons A. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations. Clin Neuropharmacol 14 3 (1991) 228-234
27. Churchyard A., Mathias C.J., Boonkongchuen P., et al. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J Neurol Neurosurg Psychiatry 63 2 (1997) 228-234
28. Churchyard A., Mathias C.J., and Lees A.J. Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal. Mov Disord 14 2 (1999) 246-251
29. Clarke A., and Jankovic J. Selegiline orally disintegrating tablet in the treatment of Parkinson's disease. Therapy 3 3 (2006) 349-356
30. Lew M.F. Selegiline orally disintegrating tablets for the treatment of Parkinson's disease. Expert Rev Neurother 5 6 (2005) 705-712
31. Zhang H., Zhang J., and Streisand J.B. Oral mucosal drug delivery: clinical pharmacokinetics and therapeutic applications. Clin Pharmacokinet 41 9 (2002) 661-680
32. Fuh J.-L., Lee R.-C., Wang S.-J., et al. Swallowing difficulty in Parkinson's disease. Clin Neurol Neurosurg 99 2 (1997) 106-112
33. Clarke A., Brewer F., Johnson E.S., et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J Neural Transm 110 11 (2003) 1241-1255
34. Heikkinen H., Nutt J.G., LeWitt P.A., et al. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease. Clin Neuropharmacol 24 3 (2001) 150-157
35. Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update. Clin Pharmacokinet 45 2 (2006) 109-136
36. Widnell K.L., and Comella C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord 20 Suppl 11 (2005) S30-S37
37. Olanow C.W. Tolcapone and hepatotoxic effects. Arch Neurol 57 2 (2000) 263-267
38. Kurth M.C., Adler C.H., Hilaire M.S., et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Neurology 48 1 (1997) 81-87
39. Rajput A.H., Martin W., Saint-Hilaire M.H., et al. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 49 4 (1997) 1066-1071
40. Adler C.H., Singer C., O'Brien C., et al. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 55 8 (1998) 1089-1095
41. Lew M., and Kricorian G. Results from a 2-year centralized tolcapone liver enzyme monitoring program. J Neurol Sci 238 Suppl 1 (2005) S363
42. Nutt J.G., Woodward W.R., Beckner R.M., et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44 (1994) 913-919
43. Brooks D.J., Sagar H., and UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74 8 (2003) 1071-1079
44. Rinne U.K., Larsen J.P., Siden A., et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51 5 (1998) 1309-1314
45. The Entacapone to Tolcapone Switch Study Investigators. Entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 22 1 (2007) 14-19
46. Frankel J.P., Kempster P.A., Bovingdon M., et al. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry 52 (1989) 1063-1067
47. Nutt J.G., Woodward W.R., Hammerstad J.P., et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. N Engl J Med 310 (1984) 483-488
48. Stacy M. Pharmacotherapy for advanced Parkinson's disease. Pharmacotherapy 20 (2000) S8-16
49. Fahn S., Oakes D., Shoulson I., et al., for the Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 24 (2004) 2498-2508
50. Luginger E., Wenning G.K., Bosch S., et al. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 15 5 (2000) 873-878
51. Snow B.J., Macdonald L., Mcauley D., et al. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clin Neuropharmacol 23 2 (2000) 82-85
52. Verhagen Metman L., Del Dotto P., Blanchet P.J., et al. Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 14 1-3 (1998) 75-82
53. Verhagen Metman L., Del Dotto P., van den Munckhof P., et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 5 (1998) 1323-1326
54. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 16 Suppl 1 (2003) S13-S19
55. Bonnet A.M., Serre I., Marconi R., et al. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine. Mov Disord 10 5 (1995) 668-671
56. Tintner R., Manian P., Gauthier P., et al. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease. Arch Neurol 62 8 (2005) 1290-1295
57. Allain H., Destée A., Petit H., et al. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. Eur Neurol 44 1 (2000) 22-30
58. Kolls B., and Stacy M. Apomorphine: a rapid rescue agent for the management of motor fluctuations in advanced Parkinson disease. Clin Neuropharmacol 29 5 (2006) 292-301
59. Dewey Jr. R.B., Hutton J.T., LeWitt P.A., et al. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58 9 (2001) 1385-1392
60. Street V., and Stacy M. Dopamine agonists. In: Pahwa R., and Lyons K.E. (Eds). Handbook of Parkinson's disease. 4th edition (2007), Informa, New York 335-348
61. Holloway R.G., Shoulson I., Fahn S., and the Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 7 (2004) 1044-1053
62. Guttman M., and the International Pramipexole-Bromocriptine Study Group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. Neurology 49 4 (1997) 1060-1065
63. Lieberman A., Ranhosky A., and Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 49 1 (1997) 162-168
64. Shill H.A., and Stacy M. Update on ropinirole in the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 5 (2009) 33-36
65. Rascol O., Brooks D.J., Korczyn A.D., et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 20 (2000) 1484-1491
66. Whone A.L., Watts R.L., Stoessl A.J., et al., REAL-PET Study Group. Slower progression in early Parkinson's disease treated with ropinirole compared with l-dopa: the REAL-PET study. Ann Neurol 54 1 (2003) 93-101
67. Hauser R.A., Rascol O., Korczyn A.D., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22 (2007) 2409-2417
68. Lieberman A., Olanow C.W., Sethi K., et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 51 4 (1998) 1057-1062
69. Pahwa R., Stacy M.A., Factor S.A., et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 68 (2007) 1108-1115
70. Driver-Dunckley E., Samanta J., and Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 3 (2003) 422-423
71. Nirenberg M.J., and Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 21 4 (2006) 524-529
72. Prescrire Editorial Staff. Hypersexuality due to dopaminergic drugs. Prescrire Int 14 80 (2005) 224
73. Etminan M., Gill S., and Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 26 6 (2003) 439-444
74. Stacy M., Hauser R., Oertel W., et al. End of dose wearing-off in Parkinson's disease: a 9-question survey assessment. Clin Neuropharmacol 29 (2006) 312-321
75. Stacy M., Bowron A., Guttman M., et al. Identification of motor and nonmotor wearing off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. Mov Disord 20 6 (2005) 726-733
76. Cristina S., Zangaglia R., Mancini F., et al. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 26 (2003) 146-150
77. Katzenschlager R., Hughes A., Evans A., et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 20 (2005) 151-157
78. Colzi A., Turner K., and Lees A.J. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 64 (1998) 573-576
79. Kanovsky P., Kubova D., Bares M., et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord 17 (2002) 188-191
80. Manson A.J., Turner K., and Lees A.J. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 17 (2002) 1235-1241
81. Stocchi F., and Olanow C.W. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology 62 (2004) S56-S63
82. Koller W., and Stacy M. Other formulations and future considerations for apomorphine for subcutaneous injection therapy. Neurology 62 (2004) S22-S26
83. Kurth M.C., Tetrud J.W., Tanner C.M., et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 43 (1993) 1698-1703
84. Solvay Pharmaceuticals. Available at:. http://www.solvaypharmaceuticals.com/products/group/product/0,30641-2-0,00.htm Accessed June 20, 2008
85. Solvay's Duodopa intestinal gel gets FDA fast track status for Parkinson's (Feb 19, 2008), AFX News Limited. http://www.forbes.com/markets/feeds/afx/2008/02/19/afx4667956.html Accessed June 30, 2008
86. Durif F., Debilly B., Galitzky M., et al. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology 62 (2004) 381-388
87. Ellis T., Cudkowicz M.E., Sexton P.M., et al. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 12 (2000) 364-369
88. Rudolf J., Grond M., Neveling M., et al. Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis. J Neural Transm 104 (1997) 1305-1311
89. Ziegenbein M., Steinbrecher A., and Garlipp P. Clozapine-induced aplastic anemia in a patient with Parkinson's disease. Can J Psychiatry 48 (2003) 352
90. Metman L.V., and O'Leary S.T. Role of surgery in the treatment of motor complications. Mov Disord 20 Suppl 11 (2005) S45-S56
91. Dueschl G., Schade-Brittinger C., Krack P., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355 (2006) 896-908
92. Schüpbach W.M.M., Maltête D., Houeto J.L., et al. Neurosurgery at an earlier stage of Parkinson disease. Neurology 68 (2007) 267-271
93. Ferreira J.J., and Rascol O. Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease. Curr Opin Neurol 13 (2000) 431-436
94. Biggins C.A., Boyd J.L., Harrop F.A., et al. A controlled, longitudinal study of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 55 (1992) 566-572
95. Buter T.C., van den Hout A., Matthews F.E., et al. Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70 (2008) 1017-1022
96. Hely M.A., Reid W.G.J., Adena M.A., et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23 (2008) 837-844
97. Dubois B., Burn D., Goetz C., et al. Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force. Mov Disord 22 (2007) 2314-2324
98. Tröster A.I. Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. Neuropsychol Rev 18 (2008) 103-119
99. Halliday G., Hely M., Reid W., et al. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 115 (2008) 409-415
100. Leroi I., Brandt J., Reich S.G., et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19 (2004) 1-8
101. Ravina B., Putt M., Siderowf A., et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76 (2005) 934-939
102. Aarsland D., Laake K., Larsen J.P., et al. Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled study. J Neurol Neurosurg Psychiatry 72 (2002) 708-712
103. Emre M., Aarsland D., Albanese A., et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 (2004) 2509-2518
104. Poewe W., Wolters E., Emre M., et al., EXPRESS Investigators. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 21 (2006) 456-461
105. Wesnes K.A., McKeith I., Edgar C., et al. Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65 (2005) 1654-1656
106. Wilkinson D.G., Passmore A.P., Bullock R., et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract 56 (2002) 441-446
107. Seeman P., Caruso C., and Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse 62 2 (2008) 149-153
108. Ravina B., Marder K., Fernandez H., et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS/NIMH work group. Mov Disord 22 (2007) 1061-1068
109. Goetz C.G., and Stebbins G.T. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43 (1993) 2227-2229
110. Goetz C.G., and Stebbins G.T. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45 (1995) 669-671
111. Fénelon G. Psychosis in Parkinson's disease: phenomenology, frequency, risk factors, and current understanding of pathophysiologic mechanisms. CNS Spectr 13 3 Suppl 4 (2008) 18-25
112. Stacy M. Managing late complications of Parkinson's disease. Med Clin North Am 83 (1999) 469-481
113. Parkinson Study Group. Low-dose clozapine for the treatment of drug induced psychosis in Parkinson's disease. N Engl J Med 340 (1999) 757-763
114. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 353 9169 (1999) 2041-2042
115. Rabey J.M., Prokhorov T., Miniovitz A., et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 22 (2007) 313-318
116. Merims D., Balas M., Peretz C., et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 29 (2006) 331-337
117. Kurlan R., Cummings J., Raman R., et al., Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68 17 (2007) 1356-1363
118. Klein C., Prokhorov T., Miniovich A., et al. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol 29 4 (2006) 215-219
119. Friedman J.H., Berman R.M., Goetz C.G., et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 21 (2006) 2078-2081
120. Ravina B., Camicioli R., Como P.G., et al. The impact of depressive symptoms in early Parkinson's disease. Neurology 69 (2007) 342-347
121. Dooneief G., Mirabello E., Bell K., et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 49 (1992) 305-307
122. Tandberg E., Larsen J.P., Aarsland D., et al. The occurrence of depression in Parkinson's disease: a community-based survey. Arch Neurol 53 (1996) 175-179
123. Borek L.L., Amick M.M., and Friedman J.H. Non-motor aspects of Parkinson's disease. CNS Spectr 11 (2006) 541-554
124. Brandt-Christensen M., Kvist K., Nilsson F.M., et al. Treatment with antiparkinson and antidepressant drugs: a register-based, pharmaco-epidemiological study. Mov Disord 22 (2007) 2037-2042
125. Antonini A., Colosimo C., Marconi R., et al., PRIAMO study group. The PRIAMO study: background, methods and recruitment. Neurol Sci 29 2 (2008) 61-65
126. Dell'Angnello G., Ceravalo R., Nuti A., et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24 (2001) 221-227
127. Kulisevsky J., Pagonabarraga J., Pascual-Sedano B., et al. Motor changes during sertraline treatment in depressed patients with Parkinson's disease. Eur J Neurol 15 (2008) 953-959
128. Seimers E.R., Shekhar A., Quaid K., et al. Anxiety and motor performance in Parkinson's disease. Mov Disord 8 (1993) 501-506
129. Witjas T., Kaphan E., Azulay J.P., et al. Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59 3 (2002) 408-413
130. Ferrara J.M., and Stacy M. Impulse control disorders and Parkinson's disease. CNS Spectr 13 (2008) 690-698
131. Fernandez H.H., and Friedman J.H. Punding on L-dopa. Mov Disord 14 (1999) 836-838
132. Evans A.H., Katzenschlager R., Paviour D., et al. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome. Mov Disord 19 (2004) 397-405
133. Stacy M. Impulse control disorder in Parkinson's disease: criteria for diagnosis. Mov Disord 23 Suppl 9 (2008) 1349-1351
134. Galpern W.R., and Stacy M. Management of impulse control disorders in Parkinson's disease. Curr Treat Options Neurol 9 (2007) 189-197
135. De Witte P., Littleton J., Parot P., et al. Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs 19 (2005) 517-537
136. Cowen M.S., Adams C., Kraehenbuehl T., et al. The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system. Addict Biol 10 (2005) 233-242
137. Stacy M. Sleep disorders in Parkinson's disease: epidemiology and management. Drugs Aging 19 (2002) 733-739
138. Van Hilten B., Hoff J.I., and Huub A.M. Sleep disruption in Parkinson's disease. Arch Neurol 51 (1995) 922-928
139. Verban D., van Rooden S.M., Visser M., et al. Nighttime sleep problems and daytime sleepiness in Parkinson's disease. Mov Disord 23 (2008) 35-41
140. Tandberg E., Larsen J.P., and Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Dis 14 (1999) 922-927
141. Comella C.L., Tanner C.M., and Ristanovic R.L. Polysomnographic sleep measures in Parkinson's disease patients with treatment induced hallucinations. Ann Neurol 34 (1993) 710-714
142. Schenck C.H., Bundlie S.R., and Mahowald M.W. Delayed emergence of a Parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 46 (1996) 388-393
143. Frucht S., Rogers J.D., Greene P.E., et al. Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52 (1999) 1908-1910
144. Hauser R.A., Gauger L., Anderson W.M., et al. Pramipexole induced somnolence and sleep episodes of daytime sleep. Mov Disord 15 (2000) 658-663
145. Adler C.H., Caviness J.N., Hentz J.G., et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 18 (2003) 287-293
146. Ondo W.G., Fayle R., Atassi F., et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 76 (2005) 1636-1639
147. Ondo W.G., Perkins T., Swick T., et al. Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 65 (2008) 1337-1340
148. Wullner U., Schmitz-Hubsch T., Antony G., et al. Autonomic dysfunction in 3414 Parkinson's disease patients enrolled in the German Network on Parkinson's disease: the effect of aging. Eur J Neurol 14 (2007) 1405-1408
149. Verbaan D., Marinus J., Visser M., et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology 69 (2007) 333-341
150. Mathers S.E., Kempster P.A., Law P.J., et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 46 (1989) 1061-1064
151. Eichhorn T.E., and Oertel W.H. Macrogol 3350/electrolyte improves constipation in Parkinson's disease and multiple system atrophy. Mov Disord 16 (2001) 1176-1177
152. Degen L., Petrig C., Studer D., et al. Effect of tegaserod on gut transit in male and female subjects. Neurogastroenterol Motil 17 (2005) 821-826
153. Sullivan K.L., Staffetti J.F., Hauser R.A., et al. Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 21 (2006) 115-116
154. Zangaglia R., Martignoni E., Glorioso M., et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 22 (2007) 1239-1244
155. Camilleri M., Kerstens R., Rykx A., et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358 22 (2008) 2344-2354
156. Kapoor S. Management of constipation in the elderly: emerging therapeutic strategies. World J Gastroenterol 14 33 (2008) 5226-5227
157. Fitzmaurice H., Fowler C.J., Rickards D., et al. Micturition disturbance in Parkinson's disease. Br J Urol 57 (1985) 652-656
158. Ransmayr G.N., Holliger S., Schletterer K., et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson's disease and Alzheimer disease. Neurology 70 (2008) 299-303
159. Brown R.G., Jahanshahi M., Quinn N., et al. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 53 (1990) 480-486
160. Bronner G., Royter V., Korczyn A.D., et al. Sexual dysfunction in Parkinson's disease. J Sex Marital Ther 30 (2004) 95-105
161. Brusa L., Petta F., Pisani A., et al. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology 68 (2007) 1455-1459
162. Brunton S., and Kuritzky L. Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg. Curr Med Res Opin 21 (2005) 71-80
163. Ouslander J.G. Management of overactive bladder. N Engl J Med 350 (2004) 786-799
164. Sahai A., Khan M.S., Arya M., et al. The overactive bladder: review of current pharmacotherapy in adults. Part 2: treatment options in cases refractory to anticholinergics. Expert Opin Pharmacother 7 (2006) 529-538
165. Hussain I.F., Brady C.M., Swinn M.J., et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 71 (2001) 371-374
166. Hillen M.E., Wagner M.L., and Sage J.I. "Subclinical" orthostatic hypotension is associated with dizziness in elderly patients with Parkinson's disease. Arch Phys Med Rehabil 77 (1996) 710-712
167. Jankovic J., Gilden J.L., Hiner B.C., et al. Neurogenic orthostatic hypotension: a double-blind placebo-controlled study with midodrine. Am J Med 95 (1993) 38-48
168. Low P.A., Gilden J.L., Freeman R., et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. JAMA 277 (1997) 1046-1051
169. Kaufmann H. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl 70 (2006) 477-484
170. Chou K.L., Evatt M., Hinson V., et al. Sialorrhea in Parkinson's disease: a review. Mov Disord 22 (2007) 2306-2313
171. Sheffield J.K., and Jankovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother 7 (2007) 637-647
172. Capaccio P., Torretta S., Osio M., et al. Botulinum toxin therapy: a tempting tool in the management of salivary secretory disorders. Am J Otolaryngol 29 (2008) 333-338